Navigation Links
Derma Sciences Receives FDA Clearance to Sell MEDIHONEY(TM) Over the Counter
Date:6/24/2008

ll give consumers the ability to have a sterilized, standardized, and regulated all-natural product in their first aid kits at home, with the knowledge that the product is safe and effective."

To date, four versions of MEDIHONEY have been cleared by the FDA for sales into the medical market, and all four were cleared for sales into the OTC market. According to a 2004 report from marketresearch.com, the United States first aid market reached $1.5 billion in 2003, and was predicted to reach $2.5 billion by 2008. One quarter of these sales are through private label brands. Drivers of increasing sales are new technologies, an increasing reliance on self-care, and the ageing population.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences Inc Allen & Caron Inc

Edward J. Q
'/>"/>

SOURCE Derma Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Phoenix Health Systems and SunGard Availability Services Partner to Deliver Data and IT Management Solutions to Community Hospitals 2Health News:Phoenix Health Systems and SunGard Availability Services Partner to Deliver Data and IT Management Solutions to Community Hospitals 3Health News:Plaques, Tangles in Brain Don't Always Lead to Alzheimer's 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 4Health News:Deadline Extended for Nominations for Jay and Rose Phillips Awards and Phillips Caregiver Award 2
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3NC State receives NSF grant to discover plant switchboards 9774 1NC State receives NSF grant to discover plant switchboards 9774 2NC State receives NSF grant to discover plant switchboards 9774 3Researchers design new graphene based nano material with magnetic properties 13810 1Researchers design new graphene based nano material with magnetic properties 13810 2Pew poll 3A 9 in 10 Iowa voters support more government oversight of food 56091 1Pew poll 3A 9 in 10 Iowa voters support more government oversight of food 56091 2
Other Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6